Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir
- 1 November 2012
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (8) , 1605-1608
Abstract
Background: Hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) clearance are associated with an improved prognosis in chronic hepatitis B (CHB) patients. These end points are more often achieved with a one-year course of pegylated interferon (PEG-IFN) compared with one year of nucleoside/nucleotide analogue therapy. However, prolonged nucleoside/nucleotide analogue therapy may result in comparable serological response rates as with PEG-IFN. Methods: We compared serological and virological response rates among HBeAg-positive CHB patients treated with long-term continuous entecavir (ETV; n=91) for a median of 92 (IQR 50–132) weeks or one year of PEG-IFN ( n=266) with comparable follow-up. Results: Median follow-up was 92 weeks (IQR 78–198) for patients treated with PEG-IFN and 92 weeks (IQR 50–132) for patients treated with ETV. Finite PEG-IFN therapy resulted in significantly higher rates of HBeAg seroconversion (adjusted hazard ratio [HR] 3.16; P<0.001) and HBsAg clearance (HR 5.66; P=0.027) when compared to prolonged ETV treatment, whereas, ETV resulted in higher rates of HBV DNA undetectability (OR 31.14; P<0.001) also after adjustment for HBV genotype and other relevant baseline factors. Conclusions: Our study shows that finite PEG-IFN is associated with a higher probability of serological, but not virological, response for HBeAg-positive CHB patients when compared to prolonged ETV, even after correction for baseline differences.Keywords
This publication has 22 references indexed in Scilit:
- Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Liver International, 2011
- Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis BGastroenterology, 2011
- Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen–Positive Chronic Hepatitis B Using on-Treatment Hepatitis B Surface Antigen DeclineHepatology, 2010
- Durability of Peginterferon Alfa-2B Treatment at 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis BHepatology, 2010
- Hepatitis B virus infectionThe Lancet, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Hepatitis B Virus InfectionNew England Journal of Medicine, 2008
- Chronic hepatitis BHepatology, 2007
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Hepatitis B e Antigen and the Risk of Hepatocellular CarcinomaNew England Journal of Medicine, 2002